Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 20/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2889580 | 1.00 | NPY5R (0.86) | NPY5R | |
| SCHEMBL3577923 | 0.89 | NPY5R (0.69) | NPY5R | |
| SCHEMBL2888180 | 0.89 | NPY5R (0.69) | NPY5R | |
| SCHEMBL1582025 | 0.84 | NPY5R (0.75) | NPY5R | |
| SCHEMBL1582026 | 0.84 | NPY5R (0.75) | NPY5R | |
| SCHEMBL2880892 | 0.83 | NPY5R (0.69) | NPY5R | |
| SCHEMBL2880894 | 0.83 | NPY5R (0.69) | NPY5R | |
| SCHEMBL2882520 | 0.82 | NPY5R (0.62) | NPY5R | |
| SCHEMBL3580585 | 0.82 | NPY5R (0.62) | NPY5R | |
| SCHEMBL2888584 | 0.80 | NPY5R (0.67) | NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060205750-A1 | Novel benzimidazole derivatives | MSD K.K. (JP) | 2006-09-14 | — | — | US | claimed |
| US-20040054177-A1 | Novel benzimidazole derivatives | MSD K.K. (JP) | 2004-03-18 | — | — | US | claimed |
| US-7803807-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-09-28 | — | — | US | disclosed |
| US-7687514-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20100048600-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | MSD K.K. (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20060205750-A1 | Novel benzimidazole derivatives | MSD K.K. (JP) | 2006-09-14 | — | — | US | disclosed |
| US-7105526-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2006-09-12 | — | — | US | disclosed |
| US-20040054177-A1 | Novel benzimidazole derivatives | MSD K.K. (JP) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054177-A1 | Novel benzimidazole derivatives | OPRM1, OPRK1, HTR7 | NPY5R 34/4885 |
| US-20060205750-A1 | Novel benzimidazole derivatives | NPY4R, NPY5R, NPY1R | NPY5R 2/4885 |
| US-20100048600-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | NPY4R, NPY5R, NPY1R | NPY5R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.